Table 2.
Clinical and pathological associations with pCR by univariate analysis. This table lists tumor characteristics (size, receptor expression, and histology), patient characteristics (age, BMI, and clinical LAD), and treatment characteristics (standard NACT versus carboplatin-containing NACT and dual HER2 blockade regimens) and their associations with pCR rates.
| Characteristic | pCR = no | pCR = yes | Test statistic |
|---|---|---|---|
| n = 83 | n = 30 | ||
| Mean (SD) | Mean (SD) | t (p) | |
| Age | 53.00 (12.8) | 46.67 (13.2) | 2.28 (0.51) |
| Initial tumor size (cm) | 3.01 (2.0) | 2.80 (1.8) | 0.55 (0.59) |
| BMI | 28.0 (7.9) | 27.4 (6.1) | 0.41 (0.37) |
|
| |||
| N (%) | N (%) | χ 2 (p) | |
|
| |||
| Clinical LAD | |||
| (i) Yes | 49 (63.6) | 16 (57.1) | 0.370 (0.545) |
| (ii) No | 24 (36.4) | 14 (42.9) | |
| Hormone rec only | |||
| (i) Yes | 29 (37.7) | 4 (13.8) | 6.00 (0.018) |
| (ii) No | 54 (62.3) | 26 (86.2) | |
| HER2+ | |||
| (i) Yes | 25 (30.1) | 18 (60.0) | 8.57 (0.003)∗∗ |
| (ii) No | 58 (69.9) | 12 (40.0) | |
| TNBC | |||
| (i) Yes | 29 (34.9) | 8 (26.7) | 0.34 (0.563) |
| (ii) No | 54 (65.1) | 22 (73.3) | |
| Time period | |||
| (i) Before | 49 (62.8) | 8 (26.7) | 11.36 (0.001)∗∗ |
| (ii) After | 29 (37.2) | 22 (73.3) | |
| Regimen | |||
| (i) Standard | 58 (81.7) | 15 (50) | 10.99 (0.004)∗∗ |
| (ii) Carboplatin-containing | 3 (4.2) | 5 (16.7) | |
| (iii) Dual HER2 blockade | 10 (14.1) | 10 (33.3) | |
BMI: body mass index; HER2: human epidermal growth factor receptor 2; hormone rec only: hormone receptor only; LAD: lymphadenopathy; NACT: neoadjuvant chemotherapy; pCR: pathological complete response; TNBC: triple negative breast cancer.
Notes. ∗∗ p < 0.01; row data does not match column data in all cases.